Samarium 153 lexidronam

Drug Profile

Samarium 153 lexidronam

Alternative Names: CYT 424; Quadramet; Samarium 153 EDTMP; Samarium Sm 153 lexidronam; Sm 153 EDTMP

Latest Information Update: 02 Apr 2015

Price : $50

At a glance

  • Originator Dow Chemical
  • Developer CIS bio international; Cytogen Corporation; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Superna Life Sciences
  • Class Analgesics; Inorganic chemicals; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain
  • Phase III Bone metastases
  • Phase II Breast cancer; Osteosarcoma; Prostate cancer
  • Phase I/II Multiple myeloma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 02 Apr 2015 Samarium 153 lexidronam is still in phase I/II trials for Multiple myeloma (Combination therapy, Recurrent) in the USA
  • 02 Apr 2015 Samarium 153 lexidronam is still in phase II trials for Prostate cancer in the USA
  • 01 Nov 2014 M.D. Anderson Cancer Center in collaboration with Cytogen complete a phase II trial in Breast Cancer in USA (NCT00429507)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top